ESG Report

Overview

The report describes 23andMe's SASB-aligned ESG reporting for Biotechnology and Pharmaceuticals. It assigns primary ESG oversight to the full Board and describes an ESG Task Force operating under Board supervision. Workforce data as of March 31, 2022 report 768 total employees, with additional gender and role diversity metrics. The report also documents initiatives to improve genetics research diversity and product equity.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2022
Period: 1 April 2021 – 31 March 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services